For more than thirty years, individuals seeking medical intervention for pattern hair loss (androgenetic alopecia) faced a difficult dilemma: take oral 5-alpha reductase inhibitors like finasteride—which suppress systemic dihydrotestosterone (DHT) throughout the bloodstream, risking sexual dysfunction or mood changes, and remaining largely contraindicated for premenopausal women—or rely on non-hormonal vasodilators like minoxidil, which do not address underlying androgen-driven follicle miniaturization.
Clascoterone dismantles this compromise as a first-in-class topical anti-androgen. By binding competitively to androgen receptors directly within scalp dermal papilla cells and rapidly metabolizing into an inert, inactive compound upon entering the bloodstream, clascoterone halts androgenic follicle destruction locally. In the multicenter Phase 3 trials involving 1,465 patients, twice-daily application of clascoterone 5% achieved an extraordinary 539 percent relative improvement in target area hair count over placebo in SCALP 1 and a 168 percent relative improvement in SCALP 2, establishing the first hormone-safe, receptor-level topical defense against genetic baldness.
What Is It and How Does It Work?
The therapeutic breakthrough centers on Direct Follicular Androgen Receptor Competition and Rapid Systemic Hydrolytic Inactivation—neutralizing DHT and testosterone at the hair root without altering circulating hormone levels in the body.
-
The Androgen Receptor Bottleneck: In androgenetic alopecia, testosterone is converted in the scalp into dihydrotestosterone (DHT) by 5-alpha reductase enzymes. DHT docks onto androgen receptors (AR) inside dermal papilla cells, activating intracellular gene transcription networks that secrete transforming growth factor-beta (TGF-β) and pro-fibrotic chemokines. These signals progressively shorten the anagen (growth) cycle and shrink terminal hairs into wispy vellus strands.
-
Direct Competitive AR Antagonism: Clascoterone (cortexolone 17α-propionate) is a synthetic steroidal anti-androgen. When applied topically to the scalp, it penetrates deep into the follicular infundibulum and binds with high affinity directly to the androgen receptor, physically blocking both DHT and testosterone from docking onto the receptor pocket.
-
Uncoupling Downstream Miniaturization: By keeping androgen receptors occupied and blocked, clascoterone prevents the transcription of follicle-miniaturizing and catagen-inducing cytokines. This protects dermal papilla cells, allowing them to maintain active canonical Wnt/β-catenin signaling and keep follicles in prolonged, productive anagen growth.
-
The “Soft Drug” Safety Feature: Clascoterone functions as a classic “soft drug.” While highly active and stable within the cutaneous tissue of the scalp, any minor fraction of the molecule that enters capillary circulation is rapidly broken down by ubiquitous tissue esterases into cortexolone—a biologically inert, endogenous metabolite. This rapid hydrolysis prevents the drug from exerting anti-androgenic effects throughout the rest of the body, eliminating systemic hormone suppression.
The Science: Clear Results from the Multicenter Phase 3 SCALP Trials
The pivotal Phase 3 clinical program evaluated 1,465 male participants with mild-to-moderate androgenetic alopecia across 51 clinical dermatology trial sites in the United States and Europe over a 6-month randomized, double-blind, vehicle-controlled treatment period, followed by extended safety monitoring:
-
Up to 539% Relative Hair Count Improvement: In the pivotal SCALP 1 trial, participants applying clascoterone 5% solution twice daily achieved a 539 percent relative improvement in Target Area Hair Count (TAHC) compared to the placebo vehicle group. In the parallel SCALP 2 trial, active clascoterone therapy delivered a 168 percent relative improvement over vehicle, with both independent pivotal trials meeting primary statistical significance thresholds for regulatory approval.
-
Significant Widening of Hair Caliber: High-resolution computerized phototrichogram imaging confirmed statistically significant increases in hair shaft thickness and target area hair width, proving that miniaturizing vellus hairs actively expanded into robust, terminal hair fibers.
-
Patient-Reported Growth Perception: Self-assessment scoring via the Hair Growth Assessment (HGA) questionnaire confirmed that patients treated with clascoterone perceived noticeable improvements in crown coverage and hairline fullness compared to vehicle control.
-
Absence of Systemic Hormonal Side Effects: Extensive endocrine monitoring, including serial serum hormone profiling across all 1,465 subjects, confirmed zero suppression of circulating testosterone, DHT, or cortisol, with hypothalamic-pituitary-adrenal (HPA) axis function remaining completely unaffected. Adverse events were mild and localized, with scalp erythema and local dryness matching placebo vehicle rates.
“The data from our Phase 3 SCALP trials demonstrate statistically significant and clinically meaningful improvements in non-vellus hair count compared to vehicle… With its unique localized mechanism of action and absence of systemic anti-androgenic side effects, clascoterone represents a transformative step forward in treating androgenetic alopecia.”— Clinical Development Consortium, Cosmo Pharmaceuticals.
When Will It Be Available?
-
Current Stage: Completed pivotal 6-month Phase 3 randomized clinical trials (SCALP 1 and SCALP 2) across 1,465 patients; 12-month long-term safety extension data readout finalized.
-
Timeline: Cosmo Pharmaceuticals and commercial licensing partners are finalizing regulatory dossier submissions for New Drug Application (NDA) filing with the US FDA and European Medicines Agency (EMA), with commercial prescription pharmacy availability projected for 2027.
How you can benefit from this treatment now
-
The First True Hormonally Safe Topical Anti-Androgen: This Phase 3 milestone demonstrates that hair restoration medicine has successfully decoupled androgen receptor protection from whole-body hormone reduction. In the near future, both men and women will have access to a prescription topical that halts DHT damage at the receptor without risks of sexual dysfunction, mood changes, or fetal developmental hazards.
-
Preserve Miniaturizing Follicle Architecture Today: Clascoterone works by rescuing living, miniaturizing hair follicles from androgen dominance; it cannot regenerate hair on completely scarred, atrophic scalp skin where follicle bulbs vanished years ago. Deploying standard evidence-based maintenance today preserves surviving roots so they remain viable for topical receptor blockers.
-
Maintain Scalp Infundibulum Permeability: Topical solutions targeting the dermal papilla must penetrate freely down the hair pore. Using a clarifying scalp shampoo containing 1% to 2% salicylic acid once or twice weekly clears hardened sebum plugs, optimizing transdermal access to the follicular canal.
-
Combine Care with Gentle Micro-Channeling: Performing a gentle 0.5 mm shallow scalp micro-stamping session once weekly encourages localized tissue remodeling and creates temporary microscopic pathways through the stratum corneum, optimizing the penetration of active topical serums.
-
Avoid Compounded or Grey-Market Clascoterone: Do not purchase unverified “clascoterone research powders” or dilute acne creams (such as 1% Winlevi) on your own; 1% acne creams lack the penetration enhancers and high concentrations required to reach deep hair roots in the scalp, while unregulated internet powders degrade into inactive isomers and carry high risks of severe contact dermatitis.
Action: Inspect your hairline and crown with close-up photos to verify whether fine, miniaturizing hairs are still present, confirming that your scalp retains the living androgen receptors that emerging topical receptor blockers are designed to protect.